Phase II trial of imiquimod and HPV therapeutic vaccination in patients with vulval intraepithelial neoplasia

[1]  A. Hoitsma,et al.  Skin cancer and (pre)malignancies of the female genital tract in renal transplant recipients , 2010, Transplant international : official journal of the European Society for Organ Transplantation.

[2]  S. H. van der Burg,et al.  Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. , 2009, The New England journal of medicine.

[3]  L. Hefler,et al.  Accuracy of Preoperative Vulva Biopsy and the Outcome of Surgery in Vulvar Intraepithelial Neoplasia 2 and 3 , 2009, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[4]  J. Hoy,et al.  A Randomized, Placebo-Controlled, Dose-Escalation Study to Determine the Safety, Tolerability, and Immunogenicity of an HPV-16 Therapeutic Vaccine in HIV-Positive Participants With Oncogenic HPV Infection of the Anus , 2009, Journal of acquired immune deficiency syndromes.

[5]  Haiwen Tang.  Cancer vaccines and immunotherapy , 2009, Human vaccines.

[6]  J. Saunders,et al.  Administration of HPV DNA vaccine via electroporation elicits the strongest CD8+ T cell immune responses compared to intramuscular injection and intradermal gene gun delivery. , 2009, Vaccine.

[7]  C. Hung,et al.  Treatment with demethylating agent, 5-aza-2'-deoxycytidine enhances therapeutic HPV DNA vaccine potency. , 2009, Vaccine.

[8]  A. Kaufmann,et al.  Enhancement of immunogenicity of a therapeutic cervical cancer DNA‐based vaccine by co‐application of sequence‐optimized genetic adjuvants , 2009, International journal of cancer.

[9]  A. Bauzá,et al.  Pemphigus‐like lesions induced by imiquimod , 2009, Clinical and experimental dermatology.

[10]  P. Judson,et al.  Vulvar cancer in young women: demographic features and outcome evaluation. , 2009, American journal of obstetrics and gynecology.

[11]  P. Coursaget,et al.  Clinician's guide to human papillomavirus immunology: knowns and unknowns. , 2009, The Lancet. Infectious diseases.

[12]  S. Garland,et al.  Human Papillomavirus Infections and Vulvar Disease Development , 2009, Cancer Epidemiology Biomarkers & Prevention.

[13]  R. Snoeck,et al.  Cidofovir: clinical experience and future perspectives on an acyclic nucleoside phosphonate analog of cytosine in the treatment of refractory and premalignant HPV-associated anal lesions , 2009, Expert opinion on pharmacotherapy.

[14]  M. Smyth,et al.  Locally Administered TLR7 Agonists Drive Systemic Antitumor Immune Responses That Are Enhanced by Anti-CD40 Immunotherapy1 , 2009, The Journal of Immunology.

[15]  R. Kurman,et al.  Human Papillomavirus Type-Distribution in Vulvar and Vaginal Cancers and Their Associated Precursors , 2009, Obstetrics and gynecology.

[16]  A. Moscicki,et al.  Cell-Mediated Immune Responses to Human Papillomavirus 16 E6 and E7 Antigens as Measured by Interferon Gamma Enzyme-Linked Immunospot in Women With Cleared or Persistent Human Papillomavirus Infection , 2009, International Journal of Gynecologic Cancer.

[17]  S. Franceschi,et al.  Prevalence and type distribution of human papillomavirus in carcinoma and intraepithelial neoplasia of the vulva, vagina and anus: A meta‐analysis , 2009, International journal of cancer.

[18]  L. Massuger,et al.  Vulvar squamous cell carcinoma development after diagnosis of VIN increases with age. , 2009, European journal of cancer.

[19]  D. D. Da Silva,et al.  Reversal of Human Papillomavirus-Specific T Cell Immune Suppression through TLR Agonist Treatment of Langerhans Cells Exposed to Human Papillomavirus Type 161 , 2009, The Journal of Immunology.

[20]  Dan Zhao,et al.  [Clinical analysis of 35 cases of vulvar intraepithelial neoplasia grade III]. , 2009, Zhonghua fu chan ke za zhi.

[21]  J. H. Price,et al.  Clinical and immunohistochemical assessment of vulval intraepithelial neoplasia following photodynamic therapy using a novel bioadhesive patch-type system loaded with 5-aminolevulinic acid. , 2009, Photodiagnosis and photodynamic therapy.

[22]  M. van Beurden,et al.  Skinning clitorectomy and skin replacement in women with vulvar intra-epithelial neoplasia. , 2009, Journal of Plastic, Reconstructive & Aesthetic Surgery.

[23]  P. Stern,et al.  Vaccination with HPV16 L2E6E7 fusion protein in GPI-0100 adjuvant elicits protective humoral and cell-mediated immunity. , 2009, Vaccine.

[24]  C. Chuang,et al.  Enhancing therapeutic HPV DNA vaccine potency through depletion of CD4+CD25+ T regulatory cells. , 2009, Vaccine.

[25]  A. Singer,et al.  Smoking and multicentric vulval intraepithelial neoplasia , 2009, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

[26]  L. Sharp,et al.  The prospective management of women with newly diagnosed vulval intraepithelial neoplasia: Clinical outcome and quality of life , 2009, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

[27]  D. Pardoll,et al.  A Phase I Trial of a Human Papillomavirus DNA Vaccine for HPV16+ Cervical Intraepithelial Neoplasia 2/3 , 2009, Clinical Cancer Research.

[28]  C. Dumitru,et al.  NK1.1+ cells mediate the antitumor effects of a dual Toll-like receptor 7/8 agonist in the disseminated B16-F10 melanoma model , 2009, Cancer Immunology, Immunotherapy.

[29]  H. Honest,et al.  Differentiated-Type Vulval Intraepithelial Neoplasia Has a High-Risk Association With Vulval Squamous Cell Carcinoma , 2008, International Journal of Gynecologic Cancer.

[30]  M. Fehr,et al.  Outcome of treated anogenital intraepithelial neoplasia among human immunodeficiency virus-infected women. , 2008, The Journal of reproductive medicine.

[31]  Ronald W. Jones,et al.  Women's perception of the outcome of the surgical management of vulvar intraepithelial neoplasia. , 2008, The Journal of reproductive medicine.

[32]  A. Giuliano,et al.  Incidence of in situ and invasive vulvar cancer in the US, 1998–2003 , 2008, Cancer.

[33]  J. M. van der Hulst,et al.  Surgery followed by Persistence of High-Grade Squamous Intraepithelial Lesions Is Associated with the Induction of a Dysfunctional HPV16-Specific T-Cell Response , 2008, Clinical Cancer Research.

[34]  L. Miller.  Toll-like receptors in skin. , 2008, Advances in dermatology.

[35]  J. Skelly,et al.  Smoking increases the risk of high-grade vaginal intraepithelial neoplasia in women with oncogenic human papillomavirus. , 2008, Gynecologic oncology.

[36]  H. Kitchener,et al.  Clinical and Immunologic Results of a Phase II Trial of Sequential Imiquimod and Photodynamic Therapy for Vulval Intraepithelial Neoplasia , 2008, Clinical Cancer Research.

[37]  F. Zijlstra,et al.  Disturbed patterns of immunocompetent cells in usual-type vulvar intraepithelial neoplasia. , 2008, Cancer research.

[38]  A. Fiander,et al.  Contribution of demographic, psychological and disease-related factors to quality of life in women with high-grade vulval intraepithelial neoplasia. , 2008, Gynecologic oncology.

[39]  T. Gambichler,et al.  Imiquimod leads to a decrease of human papillomavirus DNA and to a sustained clearance of anal intraepithelial neoplasia in HIV-infected men. , 2008, The Journal of investigative dermatology.

[40]  I. Zagon,et al.  Imiquimod Upregulates the Opioid Growth Factor Receptor to Inhibit Cell Proliferation Independent of Immune Function , 2008, Experimental biology and medicine.

[41]  M. Madeleine,et al.  A Systematic Review of the Prevalence and Attribution of Human Papillomavirus Types among Cervical, Vaginal, and Vulvar Precancers and Cancers in the United States , 2008, Cancer Epidemiology Biomarkers & Prevention.

[42]  J. Wohlfahrt,et al.  Risk factors for invasive squamous cell carcinoma of the vulva and vagina—Population‐based case–control study in Denmark , 2008, International journal of cancer.

[43]  E. Ebert,et al.  Dissection of spontaneous cytotoxicity by human intestinal intraepithelial lymphocytes: MIC on colon cancer triggers NKG2D‐mediated lysis through Fas ligand , 2008, Immunology.

[44]  I. Bassukas,et al.  Cryosurgery during topical imiquimod: a successful combination modality for lentigo maligna , 2008, International journal of dermatology.

[45]  M. Stanley.  Immunobiology of HPV and HPV vaccines. , 2008, Gynecologic oncology.

[46]  N. Aaronson,et al.  Treatment of vulvar intraepithelial neoplasia with topical imiquimod. , 2008, The New England journal of medicine.

[47]  S. H. van der Burg,et al.  Tumor-specific regulatory T cells in cancer patients. , 2008, Human immunology.

[48]  M. Falagas,et al.  Imiquimod for treatment of vulvar and vaginal intraepithelial neoplasia , 2008, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[49]  A. Sieroń,et al.  [Photodynamic therapy in vulvar intraepithelial neoplasia]. , 2008, Ginekologia polska.

[50]  N. Dupin,et al.  Study of persistence and recurrence rates in 106 patients with condyloma and intraepithelial neoplasia after CO2 laser treatment. , 2008, European journal of dermatology : EJD.

[51]  J. del Pozo,et al.  Imiquimod in mycosis fungoides. , 2008, European journal of dermatology : EJD.

[52]  S. Calvieri,et al.  Complete remission of nodular basal cell carcinoma after combined treatment with photodynamic therapy and imiquimod 5% cream. , 2008, Dermatology online journal.

[53]  T. Wu,et al.  Generation and characterization of a preventive and therapeutic HPV DNA vaccine. , 2008, Vaccine.

[54]  S. Kanodia,et al.  Recent advances in strategies for immunotherapy of human papillomavirus‐induced lesions , 2008, International journal of cancer.

[55]  S. H. van der Burg,et al.  Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity , 2008, Clinical Cancer Research.

[56]  E. Stockfleth,et al.  Clinical investigations of Toll-like receptor agonists. , 2008, Expert opinion on investigational drugs.

[57]  P. Hillemanns,et al.  Vaccination trial with HPV16 L1E7 chimeric virus‐like particles in women suffering from high grade cervical intraepithelial neoplasia (CIN 2/3) , 2007, International journal of cancer.

[58]  R. Rouzier,et al.  Épidémiologie des néoplasies vulvaires intraépithéliales , 2007 .

[59]  L. Flowers,et al.  Vulvo-vaginal cancers: risks, evaluation, prevention and early detection. , 2007, Obstetrics and gynecology clinics of North America.

[60]  M. Schön,et al.  Imiquimod: mode of action , 2007, The British journal of dermatology.

[61]  J. Zamecnik,et al.  Human Papillomavirus (HPV) Profiles of Vulvar Lesions: Possible Implications for the Classification of Vulvar Squamous Cell Carcinoma Precursors and for the Efficacy of Prophylactic HPV Vaccination , 2007, The American journal of surgical pathology.

[62]  M. Steben,et al.  Human papillomavirus infection: epidemiology and pathophysiology. , 2007, Gynecologic oncology.

[63]  O. Mathiesen,et al.  Topical imiquimod can reverse vulvar intraepithelial neoplasia: a randomised, double-blinded study. , 2007, Gynecologic oncology.

[64]  T. Le,et al.  Final results of a phase 2 study using continuous 5% Imiquimod cream application in the primary treatment of high-grade vulva intraepithelial neoplasia. , 2007, Gynecologic oncology.

[65]  S. Wilczynski,et al.  A phase II study of Hsp-7 (SGN-00101) in women with high-grade cervical intraepithelial neoplasia. , 2007, Gynecologic oncology.

[66]  Mimi Y. Kim,et al.  Heat shock fusion protein-based immunotherapy for treatment of cervical intraepithelial neoplasia III. , 2007, Gynecologic oncology.

[67]  D. Zelterman,et al.  Therapeutic vaccination of rabbits with a ubiquitin-fused papillomavirus E1, E2, E6 and E7 DNA vaccine. , 2007, Vaccine.

[68]  N. Price.  The treatment of actinic keratoses with a combination of 5-fluorouracil and imiquimod creams. , 2007, Journal of drugs in dermatology : JDD.

[69]  J. M. van der Hulst,et al.  Association of cervical cancer with the presence of CD4+ regulatory T cells specific for human papillomavirus antigens , 2007, Proceedings of the National Academy of Sciences.

[70]  A. Rudensky,et al.  Altering the distribution of Foxp3+ regulatory T cells results in tissue-specific inflammatory disease , 2007, The Journal of experimental medicine.

[71]  C. Stegbauer,et al.  Correlates of sexual function following vulvar excision. , 2007, Gynecologic oncology.

[72]  H. Kerl,et al.  Nature of Inflammatory Infiltrate in Superficial Cutaneous Malignancies During Topical Imiquimod Treatment , 2007, The American Journal of dermatopathology.

[73]  T. Iftner,et al.  TLR9 Expression and Function Is Abolished by the Cervical Cancer-Associated Human Papillomavirus Type 161 , 2007, The Journal of Immunology.

[74]  R. Rouzier,et al.  [Epidemiology of vulvar intra-epithelial neoplasias]. , 2007, Gynecologie, obstetrique & fertilite.

[75]  Jianyong Wang,et al.  The Functional Effects of Physical Interactions among Toll-like Receptors 7, 8, and 9* , 2006, Journal of Biological Chemistry.

[76]  Richard A. Moore,et al.  Cell-mediated immune responses to COPV early proteins. , 2006, Virology.

[77]  P. Altmeyer,et al.  Imiquimod treatment of anal intraepithelial neoplasia in HIV-positive men. , 2006, Archives of dermatology.

[78]  R. Clark,et al.  The Majority of Human Peripheral Blood CD4+CD25highFoxp3+ Regulatory T Cells Bear Functional Skin-Homing Receptors1 , 2006, The Journal of Immunology.

[79]  S. Marshall,et al.  Time to clearance of human papillomavirus infection by type and human immunodeficiency virus serostatus , 2006, International journal of cancer.

[80]  F. Bray,et al.  Chapter 2: The burden of HPV-related cancers. , 2006, Vaccine.

[81]  K. Knutson,et al.  Cancer Immunol Immunother DOI 10.1007/s00262-006-0194-y REVIEW , 2006 .

[82]  T. Le,et al.  Preliminary results of 5% imiquimod cream in the primary treatment of vulva intraepithelial neoplasia grade 2/3. , 2006, American journal of obstetrics and gynecology.

[83]  Christian Dannecker,et al.  Evaluation of different treatment modalities for vulvar intraepithelial neoplasia (VIN): CO(2) laser vaporization, photodynamic therapy, excision and vulvectomy. , 2006, Gynecologic oncology.

[84]  Michael R Hamblin,et al.  Photodynamic therapy and anti-tumour immunity , 2006, Nature Reviews Cancer.

[85]  D. Provencher,et al.  High‐risk human papillomavirus infection of the genital tract of women with a previous history or current high‐grade vulvar intraepithelial neoplasia , 2006, Journal of medical virology.

[86]  R. Rosales,et al.  Regression of papilloma high-grade lesions (CIN 2 and CIN 3) is stimulated by therapeutic vaccination with MVA E2 recombinant vaccine , 2006, Cancer Gene Therapy.

[87]  H. Kitchener,et al.  Prime‐boost vaccination strategy in women with high‐grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial , 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[88]  David E. Anderson,et al.  Regulatory cells and human cancer. , 2006, Seminars in cancer biology.

[89]  A. Maclean.  Vulval cancer: prevention and screening. , 2006, Best practice & research. Clinical obstetrics & gynaecology.

[90]  Helen Trottier,et al.  The epidemiology of genital human papillomavirus infection. , 2006, Vaccine.

[91]  A. Lopes,et al.  A randomized phase II trial of indole‐3‐carbinol in the treatment of vulvar intraepithelial neoplasia , 2006, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[92]  Gerd Ritter,et al.  Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[93]  H. Fiegl,et al.  The Expression of the Regulatory T Cell–Specific Forkhead Box Transcription Factor FoxP3 Is Associated with Poor Prognosis in Ovarian Cancer , 2005, Clinical Cancer Research.

[94]  A. Fiander,et al.  Clinical responses to Cidofovir applied topically to women with high grade vulval intraepithelial neoplasia. , 2005, Gynecologic oncology.

[95]  A. Stewart,et al.  Vulvar Intraepithelial Neoplasia: Aspects of the Natural History and Outcome in 405 Women , 2005, Obstetrics and gynecology.

[96]  E. Gilboa,et al.  Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. , 2005, The Journal of clinical investigation.

[97]  D. Haidopoulos,et al.  Can local application of imiquimod cream be an alternative mode of therapy for patients with high‐grade intraepithelial lesions of the vagina? , 2005, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[98]  L. Liau,et al.  The TLR7 Agonist Imiquimod Enhances the Anti-Melanoma Effects of a Recombinant Listeria monocytogenes Vaccine1 , 2005, The Journal of Immunology.

[99]  C. Gardiner,et al.  TLR7/8-Mediated Activation of Human NK Cells Results in Accessory Cell-Dependent IFN-γ Production1 , 2005, The Journal of Immunology.

[100]  S. H. van der Burg,et al.  Detection of Human Papillomavirus (HPV) 16-Specific CD4+ T-cell Immunity in Patients with Persistent HPV16-Induced Vulvar Intraepithelial Neoplasia in Relation to Clinical Impact of Imiquimod Treatment , 2005, Clinical Cancer Research.

[101]  R. Modlin,et al.  The role of toll-like receptors in the pathogenesis and treatment of dermatological disease. , 2005, The Journal of investigative dermatology.

[102]  D. Murphy,et al.  T-cell responses to human papillomavirus type 16 among women with different grades of cervical neoplasia , 2005, British Journal of Cancer.

[103]  K. Anastos,et al.  Natural history and possible reactivation of human papillomavirus in human immunodeficiency virus-positive women. , 2005, Journal of the National Cancer Institute.

[104]  P. Stern.  Immune control of human papillomavirus (HPV) associated anogenital disease and potential for vaccination. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[105]  M. Tomai,et al.  Synthetic TLR Agonists Reveal Functional Differences between Human TLR7 and TLR8 , 2005, The Journal of Immunology.

[106]  W. Winter,et al.  Vulvar Cancer in Human Immunodeficiency Virus-Seropositive Premenopausal Women: A Case Series and Review of the Literature , 2005, Journal of lower genital tract disease.

[107]  A. D. de Craen,et al.  Is the assumed natural history of vulvar intraepithelial neoplasia III based on enough evidence? A systematic review of 3322 published patients. , 2005, Gynecologic oncology.

[108]  W. Papierz,et al.  Expression of vascular endothelial growth factor (VEGF) in vulvar squamous cancer and VIN. , 2005, Polish journal of pathology : official journal of the Polish Society of Pathologists.

[109]  Daniel J. Gould,et al.  Photodynamic therapy using meta‐tetrahydroxyphenylchlorin (Foscan®) for the treatment of vulval intraepithelial neoplasia , 2004, The British journal of dermatology.

[110]  R. Pesce,et al.  Treatment of bowenoid and basaloid vulvar intraepithelial neoplasia 2/3 with imiquimod 5% cream. , 2004, The Journal of reproductive medicine.

[111]  C. Takiya,et al.  Human papillomavirus, Epstein-Barr virus and p53 mutation in vulvar intraepithelial neoplasia. , 2004, The Journal of reproductive medicine.

[112]  M. Moyal-Barracco,et al.  Treatment of undifferentiated vulvar intraepithelial neoplasia with 5% imiquimod cream: a prospective study of 12 cases. , 2004, Archives of dermatology.

[113]  R. Greenblatt,et al.  Functional Attributes of Mucosal Immunity in Cervical Intraepithelial Neoplasia and Effects of HIV Infection , 2004, Cancer Research.

[114]  Sate H Hamza,et al.  Topical imidazoquinoline therapy of cutaneous squamous cell carcinoma polarizes lymphoid and monocyte/macrophage populations to a Th1 and M1 cytokine pattern , 2004, Clinical and experimental dermatology.

[115]  George Coukos,et al.  Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.

[116]  J. M. van der Hulst,et al.  Human Papillomavirus Type 16-Positive Cervical Cancer Is Associated with Impaired CD4+ T-Cell Immunity against Early Antigens E2 and E6 , 2004, Cancer Research.

[117]  H. Kitchener,et al.  Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7). , 2004, Vaccine.

[118]  R. Ganesan,et al.  Characterizing T-cell response in low-grade and high-grade vulval intraepithelial neoplasia, study of CD3, CD4 and CD8 expressions. , 2004, Gynecologic oncology.

[119]  E. Sabo,et al.  Intratumoral CD8+ T Lymphocytes as a Prognostic Factor of Survival in Endometrial Carcinoma , 2004, Clinical Cancer Research.

[120]  S. H. van der Burg,et al.  Immunological Responses in Women with Human Papillomavirus Type 16 (HPV-16)-Associated Anogenital Intraepithelial Neoplasia Induced by Heterologous Prime-Boost HPV-16 Oncogene Vaccination , 2004, Clinical Cancer Research.

[121]  N. Kiviat,et al.  Cigarette smoking, oncogenic human papillomavirus, Ki-67 antigen, and cervical intraepithelial neoplasia. , 2004, American journal of epidemiology.

[122]  P. Howley,et al.  Interaction of the Bovine Papillomavirus E2 Protein with Brd4 Tethers the Viral DNA to Host Mitotic Chromosomes , 2004, Cell.

[123]  D. Lowy,et al.  Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. , 2004, Virology.

[124]  E. Shevach,et al.  Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance. , 2004, Seminars in immunology.

[125]  R. Flavell,et al.  Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[126]  D. Hohl,et al.  Infection with human papillomavirus alters expression of the small proline rich proteins 2 and 3 , 2004, Journal of medical virology.

[127]  N. Christensen,et al.  The Viral E4 Protein Is Required for the Completion of the Cottontail Rabbit Papillomavirus Productive Cycle In Vivo , 2004, Journal of Virology.

[128]  Francisco A. R. Garcia,et al.  ZYC101a for Treatment of High-Grade Cervical Intraepithelial Neoplasia: A Randomized Controlled Trial , 2004, Obstetrics and gynecology.

[129]  A. Fattorossi,et al.  Lymphocyte composition of tumor draining lymph nodes from cervical and endometrial cancer patients. , 2004, Gynecologic oncology.

[130]  I. Frazer.  Prevention of cervical cancer through papillomavirus vaccination , 2004, Nature Reviews Immunology.

[131]  J. Crow,et al.  TP53 mutations in vulval lichen sclerosus adjacent to squamous cell carcinoma of the vulva , 2003, British Journal of Cancer.

[132]  E. Pamer,et al.  CD8 T cell responses to infectious pathogens. , 2003, Annual review of immunology.

[133]  S. H. van der Burg,et al.  Vaccinia-expressed human papillomavirus 16 and 18 e6 and e7 as a therapeutic vaccination for vulval and vaginal intraepithelial neoplasia. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[134]  K. Egawa.  Do Human Papillomaviruses Target Epidermal Stem Cells? , 2003, Dermatology.

[135]  Lesley Morris,et al.  Organization of Human Papillomavirus Productive Cycle during Neoplastic Progression Provides a Basis for Selection of Diagnostic Markers , 2003, Journal of Virology.

[136]  H. Buck,et al.  Treatment of Vaginal Intraepithelial Neoplasia (Primarily Low Grade) with Imiquimod 5% Cream , 2003, Journal of lower genital tract disease.

[137]  H. Kitchener,et al.  Immunological and clinical responses in women with vulval intraepithelial neoplasia vaccinated with a vaccinia virus encoding human papillomavirus 16/18 oncoproteins. , 2003, Cancer research.

[138]  A. Ferenczy,et al.  Human papillomavirus and HIV coinfection and the risk of neoplasias of the lower genital tract: a review of recent developments. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[139]  G. Campagne,et al.  Successful treatment of a high-grade intraepithelial neoplasia with imiquimod, with vulvar pemphigus as a side effect. , 2003, European journal of obstetrics, gynecology, and reproductive biology.

[140]  K. Madison,et al.  Barrier function of the skin: "la raison d'être" of the epidermis. , 2003, The Journal of investigative dermatology.

[141]  Richard A. Moore,et al.  Human papillomavirus type 16 E2- and L1-specific serological and T-cell responses in women with vulval intraepithelial neoplasia. , 2003, The Journal of general virology.

[142]  M. Pawlita,et al.  Dendritic cell-based tumor vaccine for cervical cancer II: results of a clinical pilot study in 15 individual patients , 2003, Journal of Cancer Research and Clinical Oncology.

[143]  M. Stanley.  Progress in prophylactic and therapeutic vaccines for human papillomavirus infection , 2003, Expert review of vaccines.

[144]  N. R. Chu.  Therapeutic vaccination for the treatment of mucosotropic human papillomavirus-associated disease , 2003, Expert opinion on biological therapy.

[145]  J. Palefsky,et al.  Chapter 6: Immunosuppression and co-infection with HIV. , 2003, Journal of the National Cancer Institute. Monographs.

[146]  E. Wilkinson.  Welcome for the IFCPC. , 2003, Journal of lower genital tract disease.

[147]  C. Crum,et al.  Immunotherapy of human cervical high-grade cervical intraepithelial neoplasia with microparticle-delivered human papillomavirus 16 E7 plasmid DNA. , 2003, American journal of obstetrics and gynecology.

[148]  J. Kaczorowski,et al.  Incidence, clearance and predictors of human papillomavirus infection in women. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[149]  I. Jacobs,et al.  Immunohistochemical analysis of p53 in vulval intraepithelial neoplasia and vulval squamous cell carcinoma , 2003, British Journal of Cancer.

[150]  H. Kitchener,et al.  Association between human leukocyte antigen polymorphism and human papillomavirus 16-positive vulval intraepithelial neoplasia in British women. , 2003, Cancer research.

[151]  A. Protopappas,et al.  Vulvar intraepithelial neoplasia (VIN)--diagnostic and therapeutic challenges. , 2003, European journal of gynaecological oncology.

[152]  J. Sprent,et al.  T cell memory. , 2003, Annual review of immunology.

[153]  J. Orange.  Human natural killer cell deficiencies and susceptibility to infection. , 2002, Microbes and infection.

[154]  M. Campo,et al.  The bovine papillomavirus oncoprotein E5 retains MHC class I molecules in the Golgi apparatus and prevents their transport to the cell surface , 2002, Oncogene.

[155]  I. Frazer.  Vaccines for papillomavirus infection. , 2002, Virus research.

[156]  S. H. van der Burg,et al.  Enhancement of human papillomavirus (HPV) type 16 E6 and E7-specific T-cell immunity in healthy volunteers through vaccination with TA-CIN, an HPV16 L2E7E6 fusion protein vaccine. , 2002, Vaccine.

[157]  Luise Florin,et al.  Assembly and Translocation of Papillomavirus Capsid Proteins , 2002, Journal of Virology.

[158]  M. Stanley,et al.  Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential , 2002, Clinical and experimental dermatology.

[159]  Y. Modis,et al.  Atomic model of the papillomavirus capsid , 2002, The EMBO journal.

[160]  M. van Beurden,et al.  Imiquimod in the treatment of multifocal vulvar intraepithelial neoplasia 2/3. Results of a pilot study. , 2002, The Journal of reproductive medicine.

[161]  R. Kaufman,et al.  Treatment of vulvar intraepithelial neoplasia 2/3 with imiquimod. , 2002, The Journal of reproductive medicine.

[162]  J. Palefsky,et al.  Encapsulated plasmid DNA treatment for human papillomavirus 16-associated anal dysplasia: a Phase I study of ZYC101. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[163]  P. Matzinger.  The Danger Model: A Renewed Sense of Self , 2002, Science.

[164]  D. Luesley,et al.  The effects of 5% imiquimod cream on high-grade vulval intraepithelial neoplasia. , 2002, Gynecologic oncology.

[165]  J. Palefsky,et al.  Activity of HspE7, a Novel Immunotherapy, in Patients with Anogenital Warts , 2002, Diseases of the colon and rectum.

[166]  F. Frizelle,et al.  High‐grade vulval intraepithelial neoplasia (VIN 3): a retrospective analysis of patient characteristics, management, outcome and relationship to squamous cell carcinoma of the vulva 1989–1999 , 2002, The Australian & New Zealand journal of obstetrics & gynaecology.

[167]  S. Akira,et al.  Small anti-viral compounds activate immune cells via the TLR7 MyD88–dependent signaling pathway , 2002, Nature Immunology.

[168]  Susan M. Kaech,et al.  Effector and memory T-cell differentiation: implications for vaccine development. Nat Rev Immunol. , 2002 .

[169]  M. von Knebel Doeberitz.  New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections. , 2002, European journal of cancer.

[170]  Dianne Miller,et al.  Vulvar squamous cell carcinoma in young women: a clinicopathologic study of 21 cases. , 2002, Gynecologic oncology.

[171]  R. Tindle.  Immune evasion in human papillomavirus-associated cervical cancer , 2002, Nature Reviews Cancer.

[172]  M. Korbelik,et al.  Photodynamic therapy and the immune system in experimental oncology , 2002, Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology.

[173]  J. Weinberg,et al.  Successful treatment of vulvar intraepithelial neoplasia with topical imiquimod 5% cream in a lung transplanted patient. , 2002, Acta dermato-venereologica.

[174]  T. Bieber,et al.  Successful topical immunotherapy of bowenoid papulosis with imiquimod , 2001, The British journal of dermatology.

[175]  Karl Münger,et al.  Biological activities and molecular targets of the human papillomavirus E7 oncoprotein , 2001, Oncogene.

[176]  D. Lowy,et al.  Positively Charged Termini of the L2 Minor Capsid Protein Are Necessary for Papillomavirus Infection , 2001, Journal of Virology.

[177]  V. Cerundolo,et al.  Antigen Processing Defects in Cervical Carcinomas Limit the Presentation of a CTL Epitope from Human Papillomavirus 16 E61 , 2001, The Journal of Immunology.

[178]  F. Gastrell,et al.  Human papillomavirus and vulval intra-epithelial neoplasia. , 2001, Best practice & research. Clinical obstetrics & gynaecology.

[179]  Concepcion R. Diaz-Arrastia,et al.  Clinical and molecular responses in high-grade intraepithelial neoplasia treated with topical imiquimod 5%. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[180]  S. H. van der Burg,et al.  Pre-clinical safety and efficacy of TA-CIN, a recombinant HPV16 L2E6E7 fusion protein vaccine, in homologous and heterologous prime-boost regimens. , 2001, Vaccine.

[181]  C. Woodman,et al.  Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study , 2001, The Lancet.

[182]  D. Brown,et al.  Transmission of human papillomavirus type 11 infection by desquamated cornified cells. , 2001, Virology.

[183]  M. Fehr,et al.  Photodynamic therapy of vulvar intraepithelial neoplasia III using topically applied 5-aminolevulinic acid. , 2001, Gynecologic oncology.

[184]  W. R. Hart.  Vulvar intraepithelial neoplasia: historical aspects and current status. , 2001, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[185]  G Corbitt,et al.  Immunological and viral factors associated with the response of vulval intraepithelial neoplasia to photodynamic therapy. , 2001, Cancer research.

[186]  R. Barlow,et al.  Single‐episode photodynamic therapy and vulval intraepithelial neoplasia type III resistant to conventional therapy , 2000, The British journal of dermatology.

[187]  B. Beutler,et al.  Three novel mammalian toll-like receptors: gene structure, expression, and evolution. , 2000, European cytokine network.

[188]  R. Ulevitch,et al.  Cloning and characterization of a sub-family of human toll-like receptors: hTLR7, hTLR8 and hTLR9. , 2000, European cytokine network.

[189]  J. Moore,et al.  Natural HPV immunity and vaccination strategies. , 2000, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[190]  S. Wilczynski,et al.  A phase I trial of a human papillomavirus (HPV) peptide vaccine for women with high-grade cervical and vulvar intraepithelial neoplasia who are HPV 16 positive. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[191]  Ronald W. Jones,et al.  Spontaneous Regression of Vulvar Intraepithelial Neoplasia 2‐3 , 2000, Obstetrics and gynecology.

[192]  A. Moscicki,et al.  Persistence of human papillomavirus type 16 infection is associated with lack of cytotoxic T lymphocyte response to the E6 antigens. , 2000, The Journal of infectious diseases.

[193]  S. Leodolter,et al.  Trends in vulvar neoplasia. Increasing incidence of vulvar intraepithelial neoplasia and squamous cell carcinoma of the vulva in young women. , 2000, The Journal of reproductive medicine.

[194]  G. Davis,et al.  Self-administered topical imiquimod treatment of vulvar intraepithelial neoplasia. A report of four cases. , 2000, The Journal of reproductive medicine.

[195]  E. J. Mayeaux,et al.  Placebo-controlled trial of indole-3-carbinol in the treatment of CIN. , 2000, Gynecologic oncology.

[196]  N. Kiviat,et al.  Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. , 2000, The Journal of infectious diseases.

[197]  P. Stern,et al.  Multiple mechanisms underlie HLA dysregulation in cervical cancer. , 2000, Tissue antigens.

[198]  Q. Dou,et al.  Bax degradation by the ubiquitin/proteasome-dependent pathway: involvement in tumor survival and progression. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[199]  M. Plummer,et al.  Population-based study of human papillomavirus infection and cervical neoplasia in rural Costa Rica. , 2000, Journal of the National Cancer Institute.

[200]  H Stepp,et al.  Photodynamic therapy of vulvar intraepithelial neoplasia using 5‐aminolevulinic acid , 2000, International journal of cancer.

[201]  H. Grey,et al.  Detection of T Helper Responses, But Not of Human Papillomavirus-Specific Cytotoxic T Lymphocyte Responses, After Peptide Vaccination of Patients With Cervical Carcinoma , 2000, Journal of immunotherapy.

[202]  C. Janeway,et al.  Immunology Improving on Nature in the Twenty-First Century , 2000, Cell.

[203]  I. Frazer,et al.  HPV6b virus like particles are potent immunogens without adjuvant in man. , 2000, Vaccine.

[204]  T. Iftner,et al.  Induction of E6/E7 expression in cottontail rabbit papillomavirus latency following UV activation. , 1999, Virology.

[205]  G. Fleuren,et al.  Vaccination with HPV16 peptides of patients with advanced cervical carcinoma: clinical evaluation of a phase I-II trial. , 1999, European journal of cancer.

[206]  N. Husseinzadeh,et al.  Frequency of invasive cancer in surgically excised vulvar lesions with intraepithelial neoplasia (VIN 3). , 1999, Gynecologic oncology.

[207]  P. Kalinski,et al.  Final maturation of dendritic cells is associated with impaired responsiveness to IFN-gamma and to bacterial IL-12 inducers: decreased ability of mature dendritic cells to produce IL-12 during the interaction with Th cells. , 1999, Journal of immunology.

[208]  G. Shaw,et al.  Human Papillomavirus DNA Replication Compartments in a Transient DNA Replication System , 1999, Journal of Virology.

[209]  Miranda Thomas,et al.  Inhibition of Bak-induced apoptosis by HPV-18 E6 , 1998, Oncogene.

[210]  S. Modesitt,et al.  Vulvar Intraepithelial Neoplasia III: Occult Cancer and the Impact of Margin Status on Recurrence , 1998, Obstetrics and gynecology.

[211]  C. Crum,et al.  Commentary Detecting Every Genital Papilloma Virus Infection What Does It Mean , 1998 .

[212]  C. Peyton,et al.  Genotyping of 27 Human Papillomavirus Types by Using L1 Consensus PCR Products by a Single-Hybridization, Reverse Line Blot Detection Method , 1998, Journal of Clinical Microbiology.

[213]  P. Matzinger,et al.  An innate sense of danger. , 1998, Seminars in immunology.

[214]  L Beardsley,et al.  Natural history of cervicovaginal papillomavirus infection in young women. , 1998, The New England journal of medicine.

[215]  L. Dubertret,et al.  Failure of isotretinoin and interferon-alpha combination therapy for HPV-linked severe vulvar dysplasia. A report of two cases. , 1998, The Journal of reproductive medicine.

[216]  S. Tretli,et al.  Intraepithelial and Invasive Squamous Cell Neoplasia of the Vulva: Trends in Incidence, Recurrence, and Survival Rate in Norway , 1998, Obstetrics and gynecology.

[217]  C. Whitehurst,et al.  Photodynamic treatment for lower genital tract intraepithelial neoplasia , 1998, The Lancet.

[218]  K. Shah,et al.  Detection of Genital Human Papillomavirus and Associated Cytological Abnormalities Among College Women , 1998, Sexually transmitted diseases.

[219]  R. Steinman,et al.  Dendritic cells and the control of immunity , 1998, Nature.

[220]  A. D. de Craen,et al.  Human Papillomavirus DNA in Multicentric Vulvar Intraepithelial Neoplasia , 1998, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[221]  D. Lowy,et al.  The Papillomavirus Minor Capsid Protein, L2, Induces Localization of the Major Capsid Protein, L1, and the Viral Transcription/Replication Protein, E2, to PML Oncogenic Domains , 1998, Journal of Virology.

[222]  A. Ayhan,et al.  Skinning vulvectomy for the treatment of vulvar intraepithelial neoplasia 2-3: a study of 21 cases. , 1998, European journal of gynaecological oncology.

[223]  A. Ferenczy,et al.  Self-administered topical 5% imiquimod cream for external anogenital warts. HPV Study Group. Human PapillomaVirus. , 1998, Archives of dermatology.

[224]  S. Sentovich,et al.  Ano-genital neoplasia in renal transplant patients. , 1997, Annals of transplantation.

[225]  S. Napthine,et al.  Characterization of events during the late stages of HPV16 infection in vivo using high-affinity synthetic Fabs to E4. , 1997, Virology.

[226]  A. Fiander,et al.  Human papillomavirus-specific cytotoxic T lymphocytes in patients with cervical intraepithelial neoplasia grade III. , 1997, Cancer research.

[227]  A. Jackman,et al.  Inhibition of serum- and calcium-induced differentiation of human keratinocytes by HPV16 E6 oncoprotein: role of p53 inactivation. , 1997, Virology.

[228]  D. Lowy,et al.  Papillomavirus is resistant to desiccation. , 1997, The Journal of infectious diseases.

[229]  S. Stables,et al.  Trends in Squamous Cell Carcinoma of the Vulva: The Influence of Vulvar Intraepithelial Neoplasia , 1997, Obstetrics and gynecology.

[230]  A. Ferenczy,et al.  Therapeutic approaches to genital warts. , 1997, The American journal of medicine.

[231]  J. Bouwes Bavinck,et al.  HPV infections and immunosuppression. , 1997, Clinics in dermatology.

[232]  B. Moss,et al.  Cytotoxic T lymphocyte responses to E6 and E7 proteins of human papillomavirus type 16: relationship to cervical intraepithelial neoplasia. , 1997, The Journal of infectious diseases.

[233]  C. Kainz,et al.  Angiogenesis in vulvar intraepithelial neoplasia. , 1997, Gynecologic oncology.

[234]  D. Venzon,et al.  Cytokine production patterns in cervical intraepithelial neoplasia: association with human papillomavirus infection. , 1997, Journal of the National Cancer Institute.

[235]  S. Stacey,et al.  A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer , 1996, The Lancet.

[236]  M I Shafi,et al.  Vulvar intraepithelial neoplasia: long term follow up of treated and untreated women , 1996, British journal of obstetrics and gynaecology.

[237]  David Gray,et al.  Immunological Memory and Protective Immunity: Understanding Their Relation , 1996, Science.

[238]  S. Napthine,et al.  Analysis of HPV1 E4 complexes and their association with keratins in vivo. , 1996, Virology.

[239]  B. Monk,et al.  Prognostic significance of human papillomavirus DNA in vulvar carcinoma , 1995 .

[240]  M. Evander,et al.  Human Papillomavirus Infection Is Transient in Young Women: A PopulationBased Cohort Study , 1995 .

[241]  U. Hørding.  Human papillomavirus in epithelial neoplasia of the vulva and the uterine cervix. On the prevalence and possible significance of some genital HPV infections. , 1995, Danish medical bulletin.

[242]  T. Horn,et al.  Human papillomavirus (HPV) in vulvar dysplasia and carcinoma in situ , 1995, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[243]  Y. Bakri,et al.  Vulvar intraepithelial neoplasia III: a clinical study of the outcome in 113 cases with relation to the later development of invasive vulvar carcinoma. , 1995, Obstetrics and gynecology.

[244]  M. Stanley,et al.  Immunological events in regressing genital warts. , 1994, American Journal of Clinical Pathology.

[245]  R. Lijnen,et al.  VIN III (bowenoid type) and HPV infection. , 1994, The British journal of dermatology.

[246]  G. Wilbanks,et al.  Growth and differentiation of human papillomavirus type 31b positive human cervical cell lines. , 1993, Gynecologic oncology.

[247]  G. Trinchieri,et al.  Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells , 1993, The Journal of experimental medicine.

[248]  T. Dougherty.  Photodynamic therapy. , 1993, Photochemistry and photobiology.

[249]  A. Maclean,et al.  Prevalence of hepatitis B and C viruses and human immunodeficiency virus infections in women of reproductive age. , 1993, British journal of obstetrics and gynaecology.

[250]  C. Crum.  Carcinoma of the vulva: epidemiology and pathogenesis. , 1992, Obstetrics and gynecology.

[251]  J. Bock,et al.  Sexual function and somatopsychic reactions after local excision of vulvar intra‐epithelial neoplasia , 1992, Acta obstetricia et gynecologica Scandinavica.

[252]  K. Sherman,et al.  Cigarette smoking and the risk of anogenital cancer. , 1992, American journal of epidemiology.

[253]  J. Shimazaki,et al.  Changes on distribution of CD4+/CD45RA- and CD8+/CD11- cells in tumor-infiltrating lymphocytes of renal cell carcinoma associated with tumor progression. , 1992, European urology.

[254]  K. Sherman,et al.  Human papillomavirus infection in women with multicentric squamous cell neoplasia. , 1991, American journal of obstetrics and gynecology.

[255]  G. Grindlay,et al.  Studies on vaccination against papillomaviruses: prophylactic and therapeutic vaccination with recombinant structural proteins. , 1991, Virology.

[256]  L. Crawford,et al.  Specific interaction between HPV-16 E1–E4 and cytokeratins results in collapse of the epithelial cell intermediate filament network , 1991, Nature.

[257]  P. Greenberg.  Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. , 1991, Advances in immunology.

[258]  S. Neill,et al.  The epithelial changes associated with squamous cell carcinoma of the vulva: a review of the clinical, histological and viral findings in 78 women , 1990, British journal of obstetrics and gynaecology.

[259]  J L Sullivan,et al.  Severe herpesvirus infections in an adolescent without natural killer cells. , 1989, The New England journal of medicine.

[260]  M. Stanley,et al.  Properties of a non‐tumorigenic human cervical keratinocyte cell line , 1989, International journal of cancer.

[261]  E. Wilkinson,et al.  Unrecognized invasive carcinoma in vulvar intraepithelial neoplasia (VIN). , 1988, Gynecologic oncology.

[262]  J. Woodruff,et al.  The Predominance of Human Papillomavirus Type 16 in Vulvar Neoplasia , 1988, Obstetrics and gynecology.

[263]  P. Wijermans,et al.  Interferon-alpha in treatment of intraepithelial neoplasia of the lower genital tract: a case report. , 1988, European journal of obstetrics, gynecology, and reproductive biology.

[264]  A. Sedlis,et al.  A review of lower genital intraepithelial neoplasia and the use of topical 5-fluorouracil. , 1985, Obstetrical & gynecological survey.

[265]  N. Peet,et al.  Synthesis and antiallergic activity of some quinolinones and imidazoquinolinones. , 1985, Journal of medicinal chemistry.

[266]  H. Fox,et al.  Vulvar intraepithelial neoplasia and microinvasive carcinoma of the vulva. , 1984, Journal of clinical pathology.

[267]  H. Hausen,et al.  Human papillomavirus type‐16‐related DNA in genital Bowen's disease and in bowenoid papulosis , 1983, International journal of cancer.

[268]  B. K. Aikat.  Tumour immunity. , 1974, Indian journal of pathology & bacteriology.

[269]  H. Ichinose,et al.  Spontaneous regression of Bowenoid atypia of the vulva. , 1973, Obstetrics and gynecology.

[270]  E. G. Friedrich.  Reversible Vulvar Atypia: A Case Report , 1972, Obstetrics and gynecology.